VIRIDIAN THERAPEUTICS INC
BiotechVIRIDIAN THERAPEUTICS INC is a biotechnology company focused on Immunology, Metabolic, Ophthalmology.
VIRIDIAN THERAPEUTICS INC at a Glance
- Growing R&D activity with 5 trials in last 2 years
- Fast trial execution (20 months median completion)
VIRIDIAN THERAPEUTICS INC's Key Drugs
VIRIDIAN THERAPEUTICS INC's core commercial portfolio centers on LUMVOA, spanning Immunology and Metabolic — its most strategically important drugs approved in the last 15 years.
VIRIDIAN THERAPEUTICS INC's Recent FDA Approvals
VIRIDIAN THERAPEUTICS INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
VIRIDIAN THERAPEUTICS INC's Therapeutic Areas
VIRIDIAN THERAPEUTICS INC's approved drugs and pipeline span 4 therapeutic areas, led by Immunology and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VIRIDIAN THERAPEUTICS INC's Top Competitors
VIRIDIAN THERAPEUTICS INC's closest competitors by therapeutic-area and drug-target overlap include Eli Lilly, Roche, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VIRIDIAN THERAPEUTICS INC Pipeline Snapshot
VIRIDIAN THERAPEUTICS INC has 31 active clinical programs from ClinicalTrials.gov — 23 Phase 3, 8 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LUMVOA leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/8 completed
- • Speed: 20 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2026-06-26
- Latest
- 2026-06-26
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges